1
↑1
↓0
—0
Evidence suggests Psilocybin mayincreaseAdverse events.
1 studies (1 claims)
Typical dose 25 mg
Exact normalized-entity scope. Exact scope. Claims must match the selected normalized intervention and endpoint IDs; signal links are not expanded. Direction describes the stored endpoint phrase and is not a benefit/harm judgement.
1 of 1
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| psilocybin | Increases - associated with a higher risk | adverse events | Human | adult patients with MDD | 25 mg, 0.215 mg/kg, and 10 mg. | Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials.cited 2× |